Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat; Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K; CTT Collaboration trialists: A to Z trial (phase Z); Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S; AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study); Clearfield M, Downs JR, Gotto A Jr, Weis S; ALERT (Assessment of Lescol in Renal Transplantation); Fellström B, Holdaas H, Jardine A, Pedersen TR; ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial); Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L; ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events); Koren M; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial); Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H; ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependen… See abstract for full author list ➔ Wu R, et al. Among authors: probstfield jl. Br J Gen Pract. 2024 Feb 19;74(740):e189-98. doi: 10.3399/BJGP.2023.0198. Online ahead of print. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Branch KRH, Probstfield JL, Bosch J, Bhatt DL, Maggioni AP, Muehlhofer E, Avezum A, Widimsky P, Connolly SJ, Yi Q, Shestakovska O, Yusuf S, Eikelboom JW. Branch KRH, et al. Among authors: probstfield jl. Am Heart J. 2023 Apr;258:60-68. doi: 10.1016/j.ahj.2023.01.008. Epub 2023 Jan 14. Am Heart J. 2023. PMID: 36646196 Clinical Trial.
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
Gerstein HC, Wolsk E, Claggett B, Diaz R, Dickstein K, Hess S, Køber L, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Tardif JC, Pfeffer MA. Gerstein HC, et al. Among authors: probstfield jl. Diabetes Obes Metab. 2023 Apr;25(4):1125-1129. doi: 10.1111/dom.14954. Epub 2023 Jan 3. Diabetes Obes Metab. 2023. PMID: 36546588 No abstract available.
Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.
Branch KRH, Gerstein HC, Probstfield JL. Branch KRH, et al. Among authors: probstfield jl. Eur J Heart Fail. 2022 Nov;24(11):2207-2208. doi: 10.1002/ejhf.2719. Epub 2022 Oct 25. Eur J Heart Fail. 2022. PMID: 36224326 Free article. Clinical Trial. No abstract available.
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Branch KRH, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC, Jansky P, Lakshmanan M, Lanas F, Leiter LA, Pais P, Pogosova N, Raubenheimer PJ, Ryden L, Shaw JE, Sheu WHH, Temelkova-Kurktschiev T, Bethel MA, Gerstein HC, Chinthanie R, Probstfield JL. Branch KRH, et al. Among authors: probstfield jl. Eur J Heart Fail. 2022 Oct;24(10):1805-1812. doi: 10.1002/ejhf.2670. Epub 2022 Sep 20. Eur J Heart Fail. 2022. PMID: 36073143 Free article. Clinical Trial.
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Rydén L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, Yusuf S. Eikelboom JW, et al. Among authors: probstfield jl. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):786-795. doi: 10.1093/ehjcvp/pvac023. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35383832 Clinical Trial.
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.
Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Wolsk E, et al. Among authors: probstfield jl. J Am Heart Assoc. 2022 Apr 19;11(8):e021327. doi: 10.1161/JAHA.121.021327. Epub 2022 Apr 6. J Am Heart Assoc. 2022. PMID: 35383463 Free PMC article.
159 results